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Objective: To determine the role of enterokine FGF15/19 in adipose tissue thermogenic adaptations.
Methods: Circulating FGF19 and gene expression (qRT-PCR) levels were assessed in subcutaneous adipose tissue from obese human patients.
Effects of experimentally increased FGF15 and FGF19 levels in vivo were determined in mice using adenoviral and adeno-associated vectors.
Adipose tissues were characterized in FGF15-null mice under distinct cold-related thermogenic challenges. The analyses spanned metabolic
profiling, tissue characterization, histology, gene expression, and immunoblot assays.
Results: In humans, FGF19 levels are directly associated with UCP1 gene expression in subcutaneous adipose tissue. Experimental increases in
FGF15 or FGF19 induced white fat browning in mice as demonstrated by the appearance of multilocular beige cells and markers indicative of a
beige phenotype, including increased UCP1 protein levels. Mice lacking FGF15 showed markedly impaired white adipose tissue browning and a
mild reduction in parameters indicative of BAT activity in response to cold-induced environmental thermogenic challenges. This was concomitant
with signs of altered systemic metabolism, such as reduced glucose tolerance and impaired cold-induced insulin sensitization.
Conclusions: Enterokine FGF15/19 is a key factor required for adipose tissue plasticity in response to thermogenic adaptations.
 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FGF15 (and its human orthologue, FGF19) are members of the FGF
protein family; they are produced by ileal enterocytes and belong to the
subfamily of endocrine FGFs, together with FGF21 and FGF23. FGF15/
19 synthesis in ileal enterocytes is stimulated by bile acids that,
through FXR, induce transcription of the FGF15/19 genes. FGF15/19
acts on target cells through FGF receptors, mostly FGFR4, that are
predominantly expressed in the liver [1]. Similar to FGF21, the action of
FGF15/19 requires the interaction of FGFRs with the co-receptor b-
Klotho (KLB). The main recognized function of FGF15/19 is to regulate
bile acid homeostasis through its ability to inhibit the expression of
CYP7A1, which is the key enzyme in the hepatic biosynthesis of bile
acids from cholesterol [2]. FGF15/19 also participates in regulating
hepatic metabolism, and in the liver, FGF19 reportedly triggers effects
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atocarcinogenesis [4] and favor fatty liver regeneration [5].
Brown adipose tissue (BAT) activation and the acquisition of brown fat-
like properties by white adipose tissue (WAT; that is, the so-called
“browning” of WAT) are associated with enhanced energy expendi-
ture and protection against obesity and damaging metabolic conditions
such as hyperglycemia and hyperlipidemia [6]. High thermogenic re-
quirements, such as those experienced under cold environment
exposure or diet-originating stimuli, induce BAT activity and WAT
browning. Although the sympathetic nervous system is considered to
be the main driver of thermogenic BAT activation and WAT browning,
growing evidence indicates that non-sympathetic regulators are also
involved [7]. Among them, FGF21 has been identified as being involved
in eliciting BAT activity and WAT browning, although its relative
contribution to the cold- or diet-induced thermogenic activation of
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Original ArticleSeveral observations support the idea that there is cross-talk between
the intestine and thermogenic activation of adipose tissues. Manipu-
lation of the intestinal microbiota has been reported to influence BAT
activity and WAT browning in distinct experimental settings
[9,10,11,12]. The endocrine factor GLP-1 originating in the intestine is
known to induce BAT thermogenic activity and browning, mostly
through an indirect hypothalamus-mediated mechanism [13]. The gut
hormone secretin was recently shown to target BAT and elicit satiation
signaling [14]. Bariatric surgery is known to rapidly improve patients’
glucose/insulin homeostasis [15] and cause BAT activation [16],
possibly due to gut-originating signals that are not yet fully understood.
The induction of FG15/19 has been proposed to contribute to such an
effect [17]. By using a large cohort of patients representing a wide
range of BMI, we identified a significant reciprocal correlation between
BMI and circulating FGF19 levels as well as a direct correlation be-
tween plasma FGF19 levels and the expression of UCP1, which is a
marker gene for WAT browning.
Using the FGF15-null mouse model and gain-of-function approaches
based on FGF15 overexpression, we show that FGF15/19 plays a key
role in adaptive WAT browning.
2. MATERIALS AND METHODS
2.1. Human studies
Plasma and abdominal subcutaneous WAT samples were prospec-
tively collected from obese patients who underwent different surgical
procedures (cholecystectomy, abdominal hernia, and gastric bypass)
as well as non-obese healthy volunteers. Patients with hepatic dis-
eases (tumors or hepatitis C infection) or thyroid disorders were
excluded. All the subjects were recruited by the Endocrinology Service
at Dr. Josep Trueta Hospital (Girona, Spain). All of the participants were
of Caucasian origin, were assessed in the post-absorptive state, and
reported that their body weight had been stable for at least three
months before the study. This study was conducted in accordance with
the Declaration of Helsinki. Dr. Josep Trueta Hospital’s ethical com-
mittee approved the protocol, and all the patients provided written
informed consent before their inclusion after the purpose of the study
was explained to them. Samples and data from patients included in
this study were provided by the FATBANK platform promoted by the
CIBEROBN and coordinated by the IDIBGI Biobank (Biobanc IDIBGI,
B.0000872) integrated in the Spanish National Biobanks Network and
processed following standard operating procedures with the appro-
priate approval of the Ethics, External Scientific, and FATBANK Internal
Scientific committees. Anthropometrical characteristics and circulating
biochemical parameters are described in Supplementary Table 1.
Adipose samples were obtained under sterile conditions, rinsed with
PBS, frozen in liquid nitrogen, and stored at 80 C. Body mass index
(BMI) was calculated according to the formula: weight/height2 (kg/m2).
Body fat mass was measured by bioelectrical impedance. An extensive
panel of metabolic and hormonal parameters in plasma (Supplemental
Table 1) was analyzed at the certified core biochemistry laboratory at
Dr. Josep Trueta Hospital. FGF19 protein levels in plasma were




Mice were bred in the animal research facilities at the University of
Barcelona. The animals were provided a standard chow diet (Teklad
2018 global 18% protein; Envigo, Indianapolis, IN, USA) and water ad2 MOLECULAR METABOLISM 43 (2021) 101113  2020 The Authors. Published by Elsevier GmbH. Tlibitum and maintained in a temperature-controlled environment on a
12/12 h lightedark cycle. Energy intake was calculated by weighing
their food every week and assuming an energy density of 13 kJ/g. All
experiments involving animals were conducted in accordance with
European Community Council Directive 86/609/EEC and the National
Institutes of Health guidelines for the care and use of laboratory ani-
mals. All experimental procedures were approved by the Institutional
Animal Care and Use Committee of the University of Barcelona.
2.2.2. Overexpression of FGF15 and FGF19 in vivo
Three-month-old C57BL/6J mice received a single retro-orbital in-
jection with 2  1011 VP/mouse of Ad5-control or Ad5-FGF15 (n ¼ 5)
as previously described [18] or a single retro-orbital injection with
1  1010 VP/mouse of AAV8-control or AAV8-FGF19 (n ¼ 6) as pre-
viously described [4]. The mice were analyzed 1 week or 3 weeks
post-injection, respectively.
2.2.3. Studies involving Fgf15-null mice
The Fgf15-null mice and WT littermate controls were on a mixed
C57BL/6Jx129/Sv strain background as previously described [18].
Three-month-old WT and Fgf15-null mice (n ¼ 6) were housed under
standard conditions (21 C) or transferred to a cold chamber or a
temperature-controlled animal contention unit (UAN-I, TDI, Madrid,
Spain) and maintained at 4 C or 30 C, respectively, for 1 week.
2.2.4. Thermography
Surface temperatures were recorded using a T335 infrared digital
thermal imaging camera (FLIR Systems, Wilsonville, OR, USA). The
mice were shaved at the measurement sites 48 h before thermo-
graphic measurements. The resulting images were analyzed using
FLIR Quick Report 1.2 software (FLIR Systems). The maximal tem-
perature from the interscapular area corresponding to iBAT sites was
retrieved. The core temperature was determined with rectal temper-
ature measurement using a KM-1420 temperature recorder (Kane-
May Measuring Instruments, Hertfordshire, UK).
2.2.5. Mouse sampling
The mice were killed by decapitation. Their blood was collected in
heparinized tubes for plasma preparation. The liver, subcutaneous
(inguinal depot), and visceral (epididymal depot) WAT and interscapular
BAT were removed, weighed, immediately frozen in liquid nitrogen,
and stored at 80 C until processing.
For histological analysis, adipose tissues were fixed with 4% para-
formaldehyde for 24 h and stored in 70% ethanol until paraffin
blocking preparation. Paraffin-embedded tissue sections (3 mm thick)
were generated, air dried, further dried overnight at 60 C, and sub-
jected to hematoxylin and eosin staining. Lipid droplet areas, brown
adipocyte count, and iWAT adipocyte areas were measured using
open-source ImageJ software with the Adiposoft plugin as described
in [19].
For immunohistofluorescence staining, paraffin-embedded tissue
sections were deparaffinated and rehydrated and heat-induced antigen
retrieval was performed in sodium citrate buffer. Slides were washed
in TBS 1 with 0.025% Triton X-100, blocked in 10% normal serum
with 1% BSA in TBS for 2 h at room temperature (RT), and incubated
with primary rabbit anti-UCP1 antibody 1/500 (ab10983; Abcam plc,
Cambridge, UK) in TBS with 1% BSA overnight at 4 C. After rinsing the
slides in TBS 0.025% Triton X-100, the slides were incubated with
goat anti-rabbit Alexa 488 secondary antibody (A27034; Thermo Fisher
Scientific Inc., Rockford, IL, USA) 1/2000 in TBS with 1% BSA for 1 h at
RT, rinsed with TBS, stained with 50 mg/ml of propidium iodidehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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solution (P4864; SigmaeAldrich, Saint Louis, MO) for 15 min, and
mounted. Fluorescent images were obtained using a Leica DFC 360FX
camera coupled to a Leica DMIRE2 microscope.
2.2.6. Mouse measurements of circulating parameters
Blood glucose was quantified using the Accutrend System (Roche
Diagnostics GmbH, Mannheim, Germany). Circulating metabolites and
hormones were determined from mouse plasma using commercially
available kits against the following: triglycerides (TR0100; Sigmae
Aldrich), non-esterified fatty acids (434-91795 and 436-91995; Wako
Chemicals GmbH, Neuss, Germany), total bile acids (80470; Crystal
Chem Inc., Elk Grove Village, IL, USA), insulin (10-1247-01; Mercodia
AB, Uppsala, Sweden), FGF21 (RD291108200R; Biovendor), and
CXCL14/BRAK (SEB607Mu; Cloud-Clone Corp., Katy, TX, USA). For
glucose tolerance tests, glucose in aqueous solution was administered
intraperitoneally (2.5 g glucose/kg) to overnight-fasted mice, blood
was obtained from the tail 0, 15, 30, 45, 60, 90, 120, and 150 min
after glucose injection, and glycemia was measured.
2.3. Western blotting
Frozen BAT and subcutaneous WAT were homogenized in RIPA buffer
(50 mM of Tris HCl pH 7.4, 150 mM of NaCl, 1 mM of EDTA, 1% v/v
Triton X-100, and 0.1% SDS) containing a protease inhibitor cocktail
(Roche) and phosphatase inhibitors (2 mM of sodium orthovanadate,
1 mM of sodium pyrophosphate, and 10 mM of sodium fluoride).
Lysates were centrifuged at 16,000 g at 4 C for 10 min. The protein
concentration was measured using a bicinchoninic acid (BCA) protein
assay as specified by the manufacturer (Pierce, Thermo Fisher Sci-
entific, Inc.), and the samples were stored at 80 C until they were
used. The samples were resolved by SDS-polyacrylamide gel elec-
trophoresis and transferred to nitrocellulose membranes. The
membranes were blocked for 1 h at RT in TBST (10 mM of Tris pH
7.4, 140 mM of sodium chloride, and 0.1% Tween20) containing 3%
BSA. Primary antibodies were applied overnight at 4 C in TBST-3%
BSA. After incubation with HRP-labeled secondary antibodies for
1 h at RT in TBST-3% BSA, the membranes were developed with an
ECL system and their luminescence was detected using a Fujifilm
LAS-3000 CCD imaging system (GE Healthcare, Chicago, IL, USA).
For quantification, images were acquired and quantified using Multi
Gauge V3.0 (Fujifilm). The primary antibodies utilized and their di-
lutions were as follows: rabbit anti-UCP1 1/1000 (ab10983; Abcam),
rabbit anti-tyrosine hydroxylase 1/1000 (AB152; EMD Millipore,
Temecula, CA, USA), and mouse anti-b-actin 1/1000 (A1978;
SigmaeAldrich).
2.4. RNA isolation, cDNA synthesis, and real-time PCR
Dissected tissues from mice (liver, BAT, and WAT) or human subcu-
taneous adipose tissue were homogenized using a Tissue Lyser LT
(Qiagen, Germany). Total RNA from homogenized tissues was isolated
using a column affinity-based method (NucleoSpin RNA II; Machereye
Nagel, Düren, Germany). Total RNA (500 ng) was transcribed into cDNA
using TaqMan reverse-transcription reagents (Applied Biosystems/Life
Technologies, Foster City, CA, USA). For quantitative analysis of mRNA
expression, a TaqMan quantitative real-time polymerase chain reaction
(qPCR) was performed on a 7500 Real-Time PCR System (Applied
Biosystems) using the specific primer pair/probe sets presented in
Supplemental Table 12. Relative mRNA levels of target genes were
normalized with respect to that of mouse Ppia (Mm02342430_g1) or
human PPIA (Hs04194521_s1) using the comparative (2-DCT) method.
Transcript levels were considered undetectable in cases when the CT
value was >40 under our experimental conditions.MOLECULAR METABOLISM 43 (2021) 101113  2020 The Authors. Published by Elsevier GmbH. This is an open a
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Statistical analyses were conducted using GraphPad Prism software
version 5.03 (GraphPad Software Inc., San Diego, CA, USA). Student’s
t-test, ManneWhitney test, and two-way ANOVA with Tukey or Dun-
nett post hoc corrections were applied. Correlation was established
based on linear regression analysis. Differences at P  0.05 were
considered significant. *P  0.05, **P  0.01, and ***P  0.001.
3. RESULTS
3.1. Plasma FGF19 levels positively correlate with the expression
of the brown/beige marker gene UCP1 in human subcutaneous
adipose tissue
FGF19 levels were assessed in a cohort of individuals (n ¼ 98)
spanning a wide range of BMI from morbid obesity to normal weight
(for anthropometrical data, see Supplemental Table 1). Our data
indicated that there was a significant inverse correlation of FGF19
levels with BMI and fat mass (Figure 1A) in agreement with previous
reports [20]. These correlations were age- and gender-independent
(Supplemental Table 2). Biopsies of subcutaneous adipose tissue
were obtained in a subset of individuals (n ¼ 50). The expression
levels of marker genes for distinct processes associated with adipose
tissue physiopathology were analyzed and their correlations with
FGF19 levels were determined. Interestingly, the transcript levels of
UCP1, which is a marker gene for the brown/beige adipose tissue
phenotype, showed a statistically significant positive correlation with
circulating FGF19 levels (Figure 1B). Another marker gene of the BAT/
beige phenotype, such as DIO2, also showed a (non-significant) trend
toward positive correlation, whereas the transcript levels of genes
encoding general adipogenesis-related actors, such as adiponectin,
PPARG, FASN, or PLIN1 (Figure 1B) did not correlate with circulating
FGF19 levels. The association between circulating FGF19 and UCP1
mRNA levels in SAT lost statistical significance when adjusted for BMI,
suggesting that this association was closely related to the status of
individuals in relation to obesity condition.
3.2. Overexpression of FGF15 and FGF19 causes browning of WAT
The previously described findings prompted us to directly determine
the potential effects of FGF15/19 on adipose tissues in relation to
browning and thermogenesis-related adaptations in a mouse model.
Considering the marked differences between murine FGF15 and hu-
man FGF19 orthologues [21], we used a totally species-homologous
experimental approach to directly determine whether FGF15 can
promote browning of adipose tissues in mice. In the absence of a
commercially available recombinant FGF15 protein, we injected a
single retro-orbital dose of an adenoviral vector to deliver a full-length
FGF15-encoding construct (Ad-FGF15) whose hepatic expression and
delivery is a commonly used tool to increase specific protein levels in
plasma [22]. At 1 week post-injection, transcript analysis revealed that
the mRNA level of Fgf15 was induced more than 100-fold in the liver
over the almost undetectable basal level (Supplemental Table 3).
Moreover, the expression of the hepatic FGF15 target gene Cyp7a1
was strongly repressed, demonstrating that the injection increased the
biological action of FGF15. Injection with Ad-FGF15 did not significantly
modify body weight, adipose depot size, biochemical parameters such
as glycemia, insulinemia, or triglyceridemia, or the hepatic expression
of Fgf21 (Supplemental Table 3).
The experimental increase in FGF15 did not trigger any alterations in
BAT in terms of histological morphology (that is, the lipid droplet size
and number of adipocytes) (Figure 2A), the profile of thermogenesis-
related gene expression (Figure 2B and Supplemental Table 3),ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
Figure 1: Circulating FGF19 protein levels positively correlate with the expression of the browning marker gene UCP1 in subcutaneous adipose tissue of humans.
Correlation between FGF19 protein levels in plasma from obese patients, (A) BMI and fat mass (n ¼ 98), and (B) mRNA levels of UCP1, DIO2, ADIPOQ, PPARG, FASN, and PLIN1 in
subcutaneous adipose tissue (n ¼ 50). All correlations were analyzed using Spearman’s correlation except for BMI, which was analyzed by Pearson’s correlation (n ¼ 38).
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Figure 2: Overexpression of FGF15 promotes browning of subcutaneous white adipose tissue in mice. All data were obtained from 3-month-old C57BL/6J mice subjected
to adenovirus-mediated overexpression of FGF15 for 1 week. Representative hematoxylin and eosin-stained histological sections of (A) brown (BAT) (20) and quantification of lipid
droplet areas and BAT density, (D) subcutaneous white (iWAT) adipose tissues (10), and quantification of adipocyte areas. Scale: 100 mm mRNA levels of Ucp1, Dio2, and
Ppargc1a in (B) BAT and (E) iWAT. Representative image of UCP1 protein immunodetection and protein levels of UCP1 per depot in (C) BAT and (F) iWAT. Actin immunodetection
was used as a loading control. (G) UCP1 (green) and nucleus (red) immunohistofluorescence staining in iWAT. Bars indicate mean  SEM (n ¼ 6). *P  0.05 and **P  0.01
denote statistical significance for comparisons between Ad-control and Ad-FGF15 analyzed by Student’s t-test.
MOLECULAR METABOLISM 43 (2021) 101113  2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
5
Figure 3: Overexpression of human FGF19 promotes browning of subcutaneous white adipose tissue in mice. All data correspond to 3-month-old C57BL/6J mice
subjected to adeno-associated virus-mediated FGF19 overexpression for 3 weeks. Representative hematoxylin and eosin-stained histological sections of (A) BAT (20) and
quantification of lipid droplet areas and BAT density, (D) iWAT (10), and quantification of adipocyte areas. Scale: 100 mm mRNA levels of Ucp1, Dio2, and Ppargc1a in (B) BAT and
(E) iWAT. Representative pictures of UCP1 protein immunodetection and protein levels of UCP1 per depot in (C) BAT and (F) iWAT. Actin immunodetection was used as a loading
control. (G) UCP1 (green) and nucleus (red) immunohistofluorescence staining in iWAT. Bars indicate mean  SEM (n ¼ 6). *P  0.05 denotes statistical significance for
comparisons between AAV8-control and AAV8-FGF19 analyzed by Student’s t-test.
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Figure 4: The lack of FGF15 reduces browning of subcutaneous WAT in mice. All data corresponded to 3-month-old WT or Fgf15-null mice housed at 22 C. (A) Glucose
tolerance test (GTT) profile (left) and area under the GTT curve (right). (B) CXCL14 levels in plasma. Representative hematoxylin and eosin-stained histological sections of (C) BAT
(20) and quantification of lipid droplet areas and BAT density, and (E) iWAT (10) and quantification of adipocyte areas. Scale 100 mm mRNA levels of Ucp1, Dio2, Ppargc1a,
leptin, and Cxcl14 in (D) BAT and (F) iWAT. (G) UCP1 (green) and nucleus (red) immunohistofluorescence staining in iWAT. Bars indicate mean  SEM (n ¼ 6). *P  0.05,
**P  0.01, and ***P  0.001 denote statistical significance for comparisons between WT and Fgf15-null mice analyzed by Student’s t-test.
MOLECULAR METABOLISM 43 (2021) 101113  2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original Articleprotein level of UCP1 (Figure 2C), and tyrosine hydroxylase (TH) protein
abundance, indicative of the extent of sympathetic innervation. How-
ever, we observed a marked increase in subcutaneous WAT browning
as reflected by an augmented number of multilocular adipocytes
(Figure 2D), increased expression of thermogenesis- and beige-related
marker genes such as Ucp1, Dio2, and Ppargc1a (Figure 2E), and
strong induction of UCP1 protein levels (Figure 2F). The levels of TH
protein also tended to increase in iWAT in response to increased FGF15
(Figure 2F). Increased FGF15 also led to a high UCP1-expressing
adipocyte mass in iWAT, as assessed by immunohistofluorescence
(Figure 2G).
To complement the previously described study, we used a similar
approach to analyze the effects of adeno-associated virus serotype 8
(AAV8)-mediated overexpression of human FGF19 in mouse liver and
its subsequent secretion over a 3-week period. In this case, the
availability of reliable commercial FGF19 antibodies allowed us to
determine that the injection of AAV8-FGF19 in the mice yielded a
plasma concentration of FGF19 of 170  18 pg/ml, which was in
range of that observed in healthy humans (296  36 pg/ml). This
expression of FGF19 was associated with some reduction in the sizes
of iBAT and WAT depots without any major change in body weight
(Supplemental Table 4). Glycemia and triglyceridemia were also un-
altered, whereas insulin levels trended lower in the AAV8-FGF19-
injected mice. Similar to the results described above, hepatic
Cyp7a1 was massively repressed in the AAV8-FGF19-injected mice,
demonstrating that the expected biological action of FGF15 was
mimicked at this level by overexpression of human FGF19. Hepatic
Fgf21 expression and the circulating level of FGF21 were not altered by
FGF19 overexpression (Supplemental Table 4).
AAV8-FGF19 injection did not significantly modify iBAT in terms of its
histological appearance (Figure 3A), gene expression levels of Ucp1,
Dio2, Ppargc1a (Figure 3B), and Cxcl14 (Supplemental Table 4), or
protein level of UCP1 and TH (Figure 3C). In contrast, subcutaneous
WAT experienced a dramatic “browning” response to FGF19 over-
expression, with a marked appearance of smaller and typical multi-
locular beige adipocytes (Figure 3D), marked induction of Ucp1, Dio2,
and Ppargc1a expression (Figure 3E), a significant upregulation of the
UCP1 protein level (Figure 3F) and the abundance of UCP1-expressing
adipocytes (Figure 3G), and a trend to increased TH levels (Figure 3F) in
iWAT. Together, these findings indicate that increase in the protein
levels of FGF15 and FGF19 promotes the browning of subcutaneous
WAT.
3.3. Impaired WAT browning in Fgf15-null mice
The results described above prompted us to investigate the role of the
FGF15/19 system on brown and beige adipose tissue biology using the
FGF15-null mouse model, which had not previously been used for this
purpose. The initial report on the Fgf15-null mice indicated that they
lacked viability [23]. However, subsequent work found that invalidation
of FGF15 in a mixed C57BL/6/129/Sv background resulted in viable
Fgf15-null mice, and these mice were used to study the role of FGF15
in hepatic function [18]. This model enabled us to investigate for the
first time how FGF15 loss of function impacts adipose tissues.
The Fgf15-null mice housed at 21 C showed mildly reduced adiposity;
this was demonstrated by reduced sizes of iWAT and epididymal WAT
(eWAT) (Supplemental Table 5) without significant alterations in the
gross body weight. Relative to wild-type (WT) mice, the Fgf15-null
mice had unaltered food energy intake, glycemia, or insulinemia, but
showed markedly impaired glucose tolerance (Figure 4A). There was
no significant difference in the levels of triglycerides or FGF21,
although the latter showed a nonsignificant tendency to be upregulated8 MOLECULAR METABOLISM 43 (2021) 101113  2020 The Authors. Published by Elsevier GmbH. Tin the Fgf15-null mice (P ¼ 0.06) (Supplemental Table 5). Circulating
levels of CXCL14 were also reduced in the FGF15-null mice
(Figure 4B).
Hepatic gene expression analysis indicated that the Fgf15-null mice
exhibited an intense induction of the Cyp7a1 gene transcript (WT,
42.0  8.2 vs. Fgf15-null, 170.0  42.0, and P < 0.01). This was
consistent with the reported ability of FGF15 to repress this key gene of
bile acid synthesis [18] and verified the biological effectiveness of
FGF15 loss of function in the Fgf15-null mouse model. However, the
circulating total bile acid levels were not significantly altered
(Supplemental Table 5).
Histological analysis of BAT from the Fgf15-null mice did not reveal any
major changes (Figure 4C) regarding lipid droplet size or the number of
cells, and the transcript levels for key genes related to BAT-mediated
thermogenesis, such as Ucp1, Dio2, and Ppargc1a, were not signifi-
cantly modified (Figure 4D). The transcript level of leptin (an indirect
marker of adiposity) was also unchanged in the BAT of the Fgf15-null
mice. Assessment of heat production at the interscapular BAT site by
infrared thermography did not reveal any significant difference be-
tween the Fgf15-null and WT mice (Supplemental Fig. S1A). However,
the expression of the batokine Cxcl14 was dramatically downregulated
in BAT from the FGF15-null mice (Figure 4D).
In contrast, histological examination of subcutaneous iWAT revealed
that the Fgf15-null mice were characterized by a larger adipocyte size
(Figure 4E) and an important reduction in the transcript levels of genes
related to adaptive thermogenesis and beige phenotypes, such as
Ucp1, Dio2, and Ppargc1a (Figure 4F). Moreover,
immunohistofluorescence-based assessment of UCP1-expressing
adipocyte mass revealed a reduction in iWAT from the Fgf15-null
mice (Figure 4G). Thus, the Fgf15-null mice housed under a mild
thermogenic challenge (21 C) showed a reduced extent of browning
in iWAT.
3.4. Impaired adaptive plasticity of WAT to thermogenic challenges
in Fgf15-null mice
In light of the altered morphology and signs of impaired WAT browning
in the FGF15-null mice under basal and 21C-housed conditions, we
analyzed the responsiveness of mice lacking FGF15 to adaptive
thermogenic challenges. For this purpose, we exposed the mice to a 1-
week adaptation at an environmental temperature of 4 C, which
confers a high requirement for thermogenesis. Both the WT and Fgf15-
null mice could adapt to this cold challenge without any compromise in
their viability or overt sign of hypothermia. Of note, cold exposure in the
WT mice did not alter Fgf15 expression levels in the ileum
(Supplemental Table 6). After the 1-week cold challenge, the Fgf15-
null mice showed a non-significant trend toward maintaining larger
masses of iWAT and eWAT relative to the WT mice (Supplemental
Table 6). Whereas glycemia was not altered by the lack of FGF15 in
the cold-exposed mice, insulinemia was much higher in the cold-
exposed Fgf15-null mice than the cold-exposed WT mice
(Supplemental Table 6). In fact, while insulin sensitization is known to
occur in response to cold [24], the Fgf15-null mice were far less able
than the WT mice to reduce insulin levels in response to 4 C.
We analyzed the capacity of the mice maintained at 21 C to adapt to
thermoneutrality (30 C) as a second reciprocal model of adaptive
adipose tissue plasticity (in this case, suppression of thermogenic
activity) [25,26]. The body weight was not altered in the Fgf15-null
mice relative to the WT mice after both groups were exposed to
30 C, although the masses of the various WAT depots were signifi-
cantly higher in the Fgf15-null mice, showing statistical significance
for eWAT (Supplemental Table 6). The iBAT mass was also higher,his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: Fgf15-null mice exhibit impaired browning of subcutaneous WAT in response to cold. All data corresponded to 3-month-old WT or Fgf15-null mice housed at 4 C
or 30 C for 1 week. Representative hematoxylin and eosin-stained histological sections of (A) BAT (20) and (D) iWAT (10). Scale 100 mm mRNA levels of Ucp1, Dio2, Ppargc1a,
Fgf21, Bmp8b, Slc2a1, and Cxcl14 in (B) BAT and (E) iWAT. Representative images of UCP1 protein immunodetection and protein levels of UCP1 per depot in (C) BAT and (F) iWAT.
Ponceau staining was used as a loading control. Bars indicate mean  SEM (n ¼ 6). *P  0.05, **P  0.01, and ***P  0.001 denote statistical significance for comparisons
between WT and Fgf15-null mice analyzed by two-way ANOVA test with Tukey’s post hoc correction.
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Original Articlelikely due to increased fat mass. Regarding systemic parameters, there
was no significant difference in the levels of triglycerides, but a
reduction in FGF21 levels in the Fgf15-null mice vs the WT mice was
found when both groups were adapted to thermoneutrality
(Supplemental Table 6).
Although there were no significant alterations in the histological
morphology (Figure 5A), the capacity of BAT to respond to cold (4 C)
showed some signs of impairment in the Fgf15-null mice as
demonstrated by reduced transcript levels of Dio2, Ppargc1a, and
Slc2a1 (Figure 5B). However, the levels of Ucp1 transcript (Figure 5B),
UCP1 protein, and TH protein (Figure 5C) in the cold-exposed Fgf15-
null mice relative to the cold-exposed WT mice did not significantly
change. The heat production at the interscapular BAT site, which was
assessed by infrared thermography, was not significantly different in
the 4C-exposed Fgf15-null mice vs the 4C-exposed WT mice
(Supplemental Fig. S1B). However, the expression of Cxcl14 was
markedly impaired in BAT from the Fgf15-null mice maintained at 4 C
(Figure 5B).
In the mice exposed to thermoneutral conditions (30 C), the histo-
logical analysis and thermogenesis-related gene expression profiles
supported the idea that only minor changes occurred in the absence of
FGF15 in BAT. Among the tested markers, significant decreases were
seen solely in Slc2a1 and Cxcl14 (Figure 5B).
In contrast, iWAT experienced much more dramatic changes due to
thermogenic challenges in the Fgf15-null vs WT mice. Histological
analysis revealed a massive “browning” (appearance of multilocular
beige-type adipocytes) in iWAT from the WT mice exposed to 4 C,
whereas much less browning appeared in the Fgf15-null mice exposed
to cold (Figure 5D).
The inductions of Ucp1, Dio2, and Ppargc1a were significantly
impaired in iWAT from the cold-exposed Fgf15-null mice (Figure 5E).
Relative UCP1 protein levels and absolute UCP1 protein levels per iWAT
depot were significantly reduced in iWAT from the Fgf15-null mice
(Figure 5F), confirming that adaptive browning of iWAT was impaired in
the Fgf15-null mice. TH levels were also reduced in the Fgf15-null
mice relative to the WT mice in response to cold, indicating that the
enhanced sympathetic innervation associated with WAT browning was
impaired due to the lack of FGF15. The expression levels of genes
involved in adaptive thermogenesis (for example, Ucp1, Dio2, and
Bmp8b) were almost undetectable in iWAT from the 30C-exposed WT
and Fgf15-null mice (Figure 5E), while Slc2a1 and Cxcl14 were
detectable but did not show any difference due to the absence of
FGF15 at in the mice maintained at 30 C.
Similar observations were obtained for eWAT, a visceral WAT depot
that is less prone to browning than subcutaneous WAT. Although 1-
week exposure to a 4 C ambient temperature did not yield any
overt signs of morphological browning of eWAT in the WT or Fgf15-null
mice (Supplemental Fig. S2A), gene expression analysis revealed that
the mRNAs for Ucp1 and Dio2 were significantly induced in the WT
mice but not the Fgf15-null mice (Supplemental Fig. S2B). On the basis
of our results, we conclude that experimentally induced suppression of
FGF15 in mice impairs the capacity to induce WAT browning.
We determined whether the expression of cellular components of the
FGF15 responsiveness machinery in adipose tissues was affected by
thermal stress and/or FGF15 gene invalidation. Cold exposure (4 C)
resulted in a much higher expression of KLB (but not FGFR1 or FGFR4)
in iWAT from the WT and Fgf15-null mice. No such effect of cold was
found in BAT.
As complementary data, we determined the expression of a panel of
marker genes of an M1 pro-inflammatory phenotype (Nos2, Tnfa, Il6,
and Ccl2) and an alternative M2-type phenotype (Arg1, Mrc1, Il10, and10 MOLECULAR METABOLISM 43 (2021) 101113  2020 The Authors. Published by Elsevier GmbH. TArg1/Nos2 ratio) of infiltrating macrophages in mouse adipose depots
in the distinct gain- and loss-of-function experimental models
(Supplemental Tables 8e11). Despite minor significant changes, no
systematic patterns of alteration were found in response to FGF15/19-
related experimental manipulations, thus indicating that modulation of
pro- or anti-inflammatory status with adipose depots was not a key
component of the FGF15-mediated effects.
4. DISCUSSION
In this study, we found that the level of FGF19 was positively asso-
ciated with the expression of UCP1 (a key marker gene of thermogenic
activity and browning of adipose tissue) in a human cohort spanning a
wide range of body weights. This prompted us to use mouse models to
study the role of FGF15/19 as a potential mediator of intestine-
originating signaling to control the browning of adipose tissues.
There are important limitations when studying FGF15/19’s role in
energy metabolism using rodent models. For example, there is a lack
of tools for antibody-based quantification of FGF15 in rodents; only
complex methods involving capture by anti-peptide antibodies com-
bined with selected reactions monitoring mass spectrometry have
achieved such quantification [27]. Other limitations include the lack of
recombinant FGF15 and the high mortality observed in the first mouse
models of FGF15 gene invalidation [23]. These issues have dampened
experimental studies attempting to establish FGF15’s actual physio-
logical role in adipose tissue plasticity. Herein, we describe the first
study using a FGF15-null mouse model and FGF15 gain-of-function
approaches to show that FGF15 plays a key role in adaptive WAT
browning.
Previous studies have shown that overexpression or treatment of mice
with high levels of human FGF19 can improve metabolism, increase
energy expenditure, cause mild effects on BAT activity [28,29], and
promote WAT browning [30]. However, the heterologous nature of
these studies and the large divergence between human FGF19 and
mouse FGF15 made it difficult to appreciate the actual physiological
role of the FGF19/15 system in adipose tissue plasticity. In this study,
we established the presence of these effects in a totally specified
homologous system based on overexpressing FGF15 in mice. How-
ever, this pharmacological approach based on high levels of over-
expression requires further studies to determine the actual
physiological role of the FGF19/15 system in relation to adipose tissue
plasticity.
Our findings indicated that the absence of FGF15 severely impaired the
capacity of WAT to undertake browning in response to thermogenic
challenges, whereas it impacted BAT activity in a more moderate
manner. This pattern of alterations mirrored the findings in mice
subjected to an experimentally induced increase in FGF15. The pref-
erential targeting of WAT also involved the modulation of sympathetic
innervation as demonstrated by TH data. The reasons for the prefer-
ential sensitivity of WAT-versus-BAT to FGF15/19-mediated effects
were unclear, but data on increased expression of KLB in WAT (but not
BAT) in response to cold may contribute to sensitization to FGF15/19-
mediated signaling. Of note, a previous report using a heterologous
model of FGF19 treatment of mice [30] showed increased energy
expenditure associated with an intense induction of UCP1 expression in
WAT, indicative of browning, which was concordant with our findings.
Interestingly, the induction of UCP1 was found to be required for the
thermogenic action of FGF19 treatment but not for FGF19-mediated
obesity protection. These findings highlight the importance of the
FGF19/15 pathway in the regulation of energy metabolism and the
complex mechanisms involved, ranging from the control of adiposehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tissue plasticity to impaired intestinal energy absorption elicited by
altered bile acid homeostasis [30].
Our current study did not allow us to fully establish the mechanisms by
which FGF15 controls WAT browning. Direct effects of FGF15 on
brown/beige adipocytes or pre-adipocytes cannot be ruled out,
although the existing evidence suggests that indirect effects are more
important. Some reports have suggested that FGFR1 receptors present
on adipose cells can mediate the cellular action of FGF15/19 [31].
However, FGFR4, which is the main receptor accounting for the effects
of FGF15/19 [32], is poorly expressed in brown/beige adipocytes and
pre-adipocytes [1]. We found that browning-susceptible human pre-
adipocyte cells were unable to acquire a browning phenotype in
response to FGF19 in vitro (unpublished data). Thus, distinct indirect
mechanisms are likely to account for the effects of FGF5/19 on WAT
browning.
Bile acids are known to activate BAT, but suppression of FGF15 either
failed to alter (this study) or increase [18] the level of bile acids, which
is consistent with FGF15’s role as a negative regulator of bile acid
biosynthesis [2]. Thus, bile acid-mediated alterations are not likely to
account for the positive relationship between FGF15 and WAT
browning. However, studies based on the direct administration of
FGF19 to distinct brain regions that express FGFR1 and KLB revealed
positive effects on metabolism, including improved glucose tolerance,
increased energy expenditure, and BAT activation [33]. Thus, it cannot
be ruled out that the action of FGF15 in promoting WAT browning may
involve indirect centrally mediated mechanisms through the control of
sympathetic activity upon adipose tissue, which would be consistent
with our data on altered TH expression in WAT depots. However, one of
the most affected genes in BAT from FGF15-null mice is CXCL14, a
batokine that contributes to WAT browning when it is secreted by BAT
following a thermogenic stimulus [34]. CXCL14 blood levels were
concomitantly reduced in several of our experimental models in
FGF15-null mice. However, gain-of-function experiments did not
trigger increased CXCL14 expression parallel to the induction of WAT
browning, which may indicate that basal physiological CXCL14
expression is permissive for FGF15/19’s effects. However, we did not
find evidence that modulation of pro- or anti-inflammatory status
within adipose depots as expected for CXCL14 action [34] was a key
component of the FGF15-mediated effects. In any case, future
research is warranted to determine the precise involvement of CXCL14
in the FGF15-mediated browning of WAT.
Multiple reports in humans have revealed a negative correlation be-
tween FGF19 levels and obesity and type II diabetes [20,35].
Considering that WAT browning protects against metabolic diseases in
rodent models [36,37] and possibly in humans [38,39,40,41], our
findings suggest that FGF15/19 may contribute to a mechanism for
intestine-to-adipose tissue communication, thereby promoting energy
expenditure and metabolic health. In fact, the systemic effects of our
loss- and gain-of-function manipulations of FGF15 in mice (i.e.,
reduced glucose tolerance and impaired cold-induced insulin sensiti-
zation observed in the FGF15-null mice) support this notion. Further
research is needed to ascertain how the positive actions of FGF15 on
the browning of WAT could contribute to disease prevention and
metabolic health improvement in clinical settings and experimental
models.
5. CONCLUSIONS
Our study reports that the circulating level of FGF19 correlates with the
levels of the brown/beige gene marker UCP1 in subcutaneous adipose
tissue of humans. In addition, a deficit in FGF15 impairs browning ofMOLECULAR METABOLISM 43 (2021) 101113  2020 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comsubcutaneous WAT after cold challenges (4 C and 21 C), while
overexpression of FGF15 and FGF19 promotes browning in mice.
FGF15/19 constitutes an intestine-originating signaling component
that is involved in controlling adipose tissue plasticity during thermo-
genic adaptations.
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